EFFICACY AND SAFETY OF LAROTRECTINIB IN PAEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER: AN EXTENDED FOLLOW-UP

被引：0

作者：

Zwaan, C. Michel ^{[1
]}

Van Tilburg, Cornelis ^{[2
,3
]}

Doz, Francois ^{[4
,5
]}

Albert, Catherine ^{[6
]}

Blattmann, Claudia ^{[7
]}

Geoerger, Birgit ^{[8
]}

Dubois, Steven ^{[9
]}

Federman, Noah ^{[10
]}

Mascarenhas, Leo ^{[11
]}

Nagasubramanian, Rama ^{[12
]}

Pappo, Alberto ^{[13
]}

Watt, Tanya ^{[14
]}

Norenberg, Ricarda ^{[15
]}

Dima, Laura ^{[16
]}

De la Cuesta, Esther ^{[17
]}

Laetsch, Theodore ^{[18
]}

Xu, Ruihua ^{[19
]}

机构：

[1] Princess Maxima Ctr Pediat Oncol, Stem Cell Transplantat Unit, Utrecht, Netherlands

[2] ErasmusMC Sophias Childrens Hosp, Pediat Oncol, Rotterdam, Netherlands

[3] Heidelberg Univ Hosp, German Canc Res Ctr DKFZ, Hopp Childrens Canc Ctr Heidelberg kitz, Heidelberg, Germany

[4] SIREDO Oncol Ctr Care, Inst Curie, Innovat & Res Children & AYA Canc, Paris, France

[5] Univ Paris Cite, Pediat, Paris, France

[6] Univ Washington Sch Med, Seattle Childrens Hosp, Dept Hematol Oncol, Seattle, WA USA

[7] Olgahospital, Dept Haematol & Oncol, Stuttgart, Germany

[8] Univ Paris Saclay, Gustave Roussy Canc Ctr, Dept Pediat & Adolescent Oncol, Villejuif, France

[9] Dana Farber Hosp, Childrens Canc & Blood Disorders Ctr, Boston, MA USA

[10] David Geffen Sch Med, UCLA Jonsson Comprehensive Canc Ctr, Pediat Hematol Oncol, Los Angeles, CA USA

[11] Univ Southern Calif Keck Sch Med, Childrens Hosp Angeles, Canc & Blood Dis Inst, Dept Hematol Oncol, Los Angeles, CA USA

[12] Childrens Hosp, Dept Hematol Oncol, Orlando, FL USA

[13] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN USA

[14] Univ Texas, SouthWestern Med Ctr, Dept Pediat, Austin, TX USA

[15] Chrestos Concept GmbH Co KG, Essen, Germany

[16] Bayer HealthCare SAS, Med Affairs, Garenne Colombes, France

[17] Bayer HealthCare Pharmaceut Inc, Oncol, Whippany, NJ USA

[18] Univ Pennsylvania, Childrens Hosp Philadelphia, Dev Therapeut Program, Philadelphia, PA USA

[19] Sun Yat sen Univ Canc Ctr, Dept Med Oncol, Guangzhou, Peoples R China

来源：

PEDIATRIC BLOOD & CANCER | 2022年 / 69卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP379

引用

页码：S324 / S325

页数：2

共 50 条

[41] ON-TRK: A NON-INTERVENTIONAL STUDY OF LAROTRECTINIB IN PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION SOLID TUMORS
Tabatabai, Ghazaleh
Trent, Jonathan
Novello, Silvia
Passiglia, Francesco
Burcoveanu, Domnita-Ileana
Norenberg, Ricarda
Laetsch, Theodore
NEURO-ONCOLOGY, 2023, 25
[42] Efficacy and Safety of Larotrectinib in Pediatric Patients with Non-Central Nervous System (CNS) Tropomyosin Receptor Kinase (TRK) Fusion-Positive Cancer: An Expanded Dataset
Van Tilburg, C.
Albert, C.
Bielack, S.
Dubois, S.
Federman, N.
Geoerger, B.
Nagasubramanian, R.
Pappo, A.
Norenberg, R.
Dima, L.
De La Cuesta, E.
Zhang, Y.
Doz, F.
Laetsch, T.
PEDIATRIC BLOOD & CANCER, 2021, 68 : S54 - S54
[43] Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system tumors.
Perreault, Sebastien
van Tilburg, Cornelis Martinus
Geoerger, Birgit
Nysom, Karsten
Ora, Ingrid
Gavrilovic, Igor T.
Norenberg, Ricarda
Dima, Laura
De La Cuesta, Esther A.
Drilon, Alexander E.
Doz, Francois P.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[44] EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT AND PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
Doz, Francois
van Tilburg, Cornelis M.
Geoerger, Birgit
Nysom, Karsten
Ora, Ingrid
Boni, Valentina
Chisholm, Julia
Chung, Hyun Cheol
DuBois, Steven G.
Gallego Melcon, Soledad
Gerber, Nicolas U.
Goto, Hiroaki
Grilley-Olsen, Juneko E.
Hansford, Jordan R.
Hong, David S.
Italiano, Antoine
Kang, Hyoung Jin
Capra, Michael
Schulte, Johannes H.
Stefanowicz, Joanna
Tahara, Makoto
Ziegler, David S.
Gavrilovic, Igor T.
Norenberg, Ricarda
Dima, Laura
De La Cuesta, Esther
Laetsch, Theodore W.
Drilon, Alexander
Perreault, Sebastien
NEURO-ONCOLOGY, 2021, 23 : 73 - 74
[45] The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.
Hyman, David Michael
Laetsch, Theodore Willis
Kummar, Shivaani
DuBois, Steven G.
Farago, Anna F.
Pappo, Alberto S.
Demetri, George D.
El-Deiry, Wafik S.
Lassen, Ulrik Niels
Dowlati, Afshin
Brose, Marcia S.
Boni, Valentina
Turpin, Brian
Nagasubramanian, Ramamoorthy
Cruickshank, Scott
Cox, Michael Craig
Ku, Nora C.
Hawkins, Douglas S.
Hong, David S.
Drilon, Alexander E.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
[46] Activity of Larotrectinib in Tropomyosin Receptor Kinase Fusion Lung Cancer
Farago, A. F.
Kummar, S.
Moreno, V.
Patel, J.
Lassen, U.
Rosen, L.
Childs, B. H.
Hyman, D. M.
Drilon, A.
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) : S28 - S28
[47] Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer
Wong, Derek
Yip, Stephen
Sorensen, Poul H.
PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (03) : 1385 - 1399
[48] ACTIVITY OF LAROTRECTINIB IN PEDIATRIC TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
Goto, Hiroaki
Geoerger, Birgit
DuBois, Steven G.
Grilley-Olson, Juneko E.
van Tilburg, Cornelis M.
Schulte, Johannes
Kang, Hyoung Jin
Tahara, Makoto
Boni, Valentina
Perreault, Sebastien
Capra, Michael
Reeves, John A.
Brega, Nicoletta
Childs, Barrett H.
Laetsch, Theodore W.
Ziegler, David S.
Doz, Francois
NEURO-ONCOLOGY, 2020, 22 : 305 - 305
[49] Activity of larotrectinib, a highly selective inhibitor of tropomyosin receptor kinase, in TRK fusion breast cancers
Meric-Bernstam, F.
Shukla, N.
Peled, N.
Landman, Y.
Onitilo, A.
Montez, S.
Ku, N. C.
Hyman, D. M.
Drilon, A.
Hong, D. S.
CANCER RESEARCH, 2019, 79 (04)
[50] Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer
Laetsch, Theodore W.
Hong, David S.
CLINICAL CANCER RESEARCH, 2021, 27 (18) : 4974 - 4982

← 1 2 3 4 5 →